MRK:NYE-Merck & Company Inc. (new)

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 62.07

Change

+3.41 (+5.81)%

Market Cap

USD 169.11B

Volume

0.05B

Yahoo Analyst Target

USD 65.23 (5.09%)

STA Analyst Target

N/A
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

+1.10 (+0.75%)

USD 394.54B
PFE Pfizer Inc.

+0.06 (+0.16%)

USD 218.16B
NVS Novartis AG

+0.08 (+0.09%)

USD 203.20B
ABBV AbbVie Inc.

+2.15 (+2.14%)

USD 163.62B
SNY Sanofi American Depositary Sha..

+0.13 (+0.29%)

USD 113.03B
ABT Abbott Laboratories

-0.40 (-0.68%)

USD 101.72B
BMY Bristol-Myers Squibb Company

-2.89 (-4.60%)

USD 98.07B
GSK GlaxoSmithKline PLC

+0.42 (+1.12%)

USD 94.00B
LLY Eli Lilly and Company

-1.69 (-1.94%)

USD 93.91B
AZN Astrazeneca PLC

-0.66 (-1.85%)

USD 88.61B

ETFs Containing MRK

IHE iShares U.S. Pharmaceutic.. 7.53 % 0.44 %

-0.97 (0.58%)

USD 0.57B
PPH VanEck Vectors Pharmaceut.. 4.90 % 0.35 %

-0.10 (0.58%)

USD 0.30B
XLV SPDR Select Sector Fund -.. 4.72 % 0.14 %

+0.43 (+0.58%)

USD 17.56B
IYH iShares U.S. Healthcare 4.65 % 0.44 %

+0.62 (+0.58%)

USD 2.04B
FHLC Fidelity MSCI Health Care.. 4.20 % 0.08 %

+0.09 (+0.58%)

USD 0.97B
VHT Vanguard Health Care 4.19 % 0.10 %

+0.25 (+0.58%)

USD 7.51B
FTXH First Trust Nasdaq Pharma.. 3.95 % 0.60 %

-0.24 (0.58%)

USD 2.22M
IXJ iShares Global Healthcare 3.29 % 0.48 %

+0.06 (+0.58%)

USD 1.70B
JHMH John Hancock Multifactor .. 3.01 % 0.50 %

+0.18 (+0.58%)

USD 0.04B
QDF FlexShares Quality Divide.. 2.73 % 0.37 %

-0.14 (0.58%)

USD 2.01B
QDEF FlexShares Quality Divide.. 2.41 % 0.37 %

-0.07 (0.58%)

USD 0.33B
QDYN FlexShares Quality Dynami.. 2.41 % 0.37 %

N/A

USD 0.06B
RNDV First Trust US Equity Div.. 2.29 % 0.00 %

+0.13 (+0.58%)

USD 0.01B
FLQD Franklin LibertyQ Global .. 2.00 % 0.45 %

+0.12 (+0.58%)

USD 0.03B
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

+0.76 (+0.58%)

USD 0.12B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.31% 87% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.31% 87% B+ 93% A
Trailing 12 Months  
Capital Gain -0.43% 30% F 29% F
Dividend Return 3.03% 59% F 47% F
Total Return 2.60% 35% F 27% F
Trailing 5 Years  
Capital Gain 45.91% 56% F 65% D
Dividend Return 21.27% 80% B- 63% D
Total Return 67.18% 50% F 65% D
Average Annual (5 Year Horizon)  
Capital Gain 8.31% 57% F 69% D+
Dividend Return 11.66% 61% D- 72% C-
Total Return 3.35% 65% D 59% F
Risk Return Profile  
Volatility (Standard Deviation) 14.26% 78% C+ 53% F
Risk Adjusted Return 81.78% 78% C+ 69% D+
Market Capitalization 167.96B 86% B 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.90 9% F 10% F
Price/Book Ratio 4.29 35% F 22% F
Price / Cash Flow Ratio 5.56 26% F 18% F
Price/Free Cash Flow Ratio 39.28 22% F 14% F
Management Effectiveness  
Return on Equity 7.22% 22% F 44% F
Return on Invested Capital 7.90% 39% F 52% F
Return on Assets 3.02% 30% F 55% F
Debt to Equity Ratio 66.75% 59% F 56% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector